The United States Patent and Trademark Office (USPTO) has granted Insmed Incorporated US Patent Number 9,566,234, titled, "Systems for treating pulmonary infections," the company said. The patent's claims relate to the use of Insmed's Arikayce liposomal amikacin inhalation solution for the treatment of nontuberculous mycobacteria (NTM) and other pulmonary infections. … [Read more...] about Insmed announces new US patent for Arikayce inhaled amikacin
Business
Penthrox methoxyflurane inhaler launched in France and Belgium
According to Medical Developments International (MVP), Mundipharma has launched the company's Penthrox methoxyflurane inhaler for or the treatment of moderate to severe pain in trauma patients in France and Belgium, triggering a milestone payment of $2.0 million to MVP. Mundipharma owns the rights to Penthrox in most of Europe outside of the UK and Ireland, where … [Read more...] about Penthrox methoxyflurane inhaler launched in France and Belgium
GSK launches OTC Flonase Sensimist fluticasone furoate nasal spray in US
GSK Consumer Healthcare has announced the US launch of Flonase Sensimist fluticasone furoate nasal spray for the once-daily treatment of seasonal and perennial allergy symptoms. The FDA approved Flonase Sensimist, an over-the-counter version of Veramyst, in August 2016. GSK has been marketing an OTC fluticasone propionate nasal spray as Flonase Allergy Relief in … [Read more...] about GSK launches OTC Flonase Sensimist fluticasone furoate nasal spray in US
Impel NeuroPharma announces agreement with Camargo Pharmaceutical Services
According to intranasal drug developer Impel NeuroPharma, the company has signed service agreements with 505(b)(2) development specialist Camargo Pharmaceutical Services. Camargo will provide development services for products based on Impel's Precision Olfactory Delivery (PODTM) intranasal delivery platform. In December 2016, Impel announced that it had raised up … [Read more...] about Impel NeuroPharma announces agreement with Camargo Pharmaceutical Services
MannKind launches Afrezza titration pack, expands sales force
MannKind Corporation has announced the availability of a new titration pack which includes 60 each of 4, 8, and 12 unit cartridges of Afrezza inhalation powder. The company already offers a titration pack that includes 90 each of 4 and 8 unit cartridges, which it says accounts for nearly 25% of Afrezza units dispensed on a weekly basis. According to the company, … [Read more...] about MannKind launches Afrezza titration pack, expands sales force
Beximco joint venture with BioCare includes new GMP inhaler facility
Bangladeshi generics company Beximco Pharmaceuticals announced that it has entered into a joint venture with Malaysian pharma company BioCare and said that the first joint project, an MDI manufacturing facility in Seri Iskandar Pharmaceutical Park, Perak, Malaysia, has already received GMP approval from the Malaysian Ministry of Health. Beximco, which will own 30% … [Read more...] about Beximco joint venture with BioCare includes new GMP inhaler facility
Pulmatrix announces $5 million registered direct offering
Inhaled drug developer Pulmatrix has announced an agreement to sell approximately 2 million shares of its common stock to institutional investors at $2.50 per share in a registered direct offering expected to generate net proceeds of approximately $4.5 million. Closing is expected on February 2, 2017, the company said, and proceeds will be used to pay indebtedness … [Read more...] about Pulmatrix announces $5 million registered direct offering
Cipla launches the Synchrobreathe inhaler in South Africa
Cipla has launched its Synchrobreathe breath actuated inhaler in South Africa, the company announced. In 2015, Cipla had said that it expected to launch the inhaler by the end of that year. Cipla Medpro CEO Paul Miller said, “Incorrect use of inhalers and non-adherence to treatment are major contributors to the poor levels of asthma control we experience in South … [Read more...] about Cipla launches the Synchrobreathe inhaler in South Africa
NasoShield developer Altimmune to merge with PharmAthene
Altimmune, which is developing intranasal vaccines against influenza and anthrax, is set to merge with vaccine developer PharmAthene, the companies have announced. Altimmune will become a wholly-owned subsidiary of PharmAthene subject to stockholder approval of the all-stock transaction, and the combined company will operate under the name Altimmune. After years … [Read more...] about NasoShield developer Altimmune to merge with PharmAthene
Mast Therapeutics to merge with Savara
AIR001 developer Mast Therapeutics will merge with AeroVanc and Molgradex developer Savara, the companies have announced. Savara's current management team will lead the combined company, which will be called Savara Inc and which will trade under a new stock ticker symbol. After the merger, current Savara stockholders will own ~76% of the combined company, and current … [Read more...] about Mast Therapeutics to merge with Savara